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Abnormal mitogen-activated protein kinase signaling in dilated cardiomyo-
pathy caused by lamin A/C gene mutation
Antoine Muchir (1), Wei Wu (2), Jason Choi (2), Howard J. Worman (2) 
(1) U974 – Inserm, Paris cedex 13, France – (2) Columbia University, New York, 
USA.
We interrogated the transcriptome in heart tissue from Lmna H222P/H222P mice, 
a mouse model of cardiomyopathy caused by lamin A/C gene (LMNA) mutation, and 
found that the extracellular signal-regulated kinase 1/2 (ERK1/2), Jun N-terminal kinase 
(JNK) and p38 branches of the mitogen-activated protein (MAP) kinase signaling 
pathway were abnormally hyperactivated prior to the onset of signifi cant cardiac 
impairment. Biochemical analysis of hearts from Lmna H222P/H222P mice showed 
enhanced activation of the branches of MAP kinases prior to and after the onset of 
heart disease as well as in hearts from human subjects with cardiomyopathy caused by 
LMNA mutations. Treatment of Lmna H222P/H222P mice with selumetinib, SP600125 
and ARRY-371797, inhibitors of the ERK1/2, JNK and p38 branches respectively, 
prevented left ventricular dilatation and deterioration of fractional shortening compared 
with placebo-treated mice. These results demonstrate that three different branches 
of the MAP kinase signaling pathway with overlapping consequences are involved 
in the pathogenesis of cardiomyopathy caused by LMNA mutations. They further 
suggest that pharmacological inhibition of these signaling may be useful in the 
treatment of this disease.
329
Molecular diagnosis of inherited cardiomyopathies and arrhythmias by 
custom target capture system of 76 genes and sequencing with Next Generation 
Sequencing (NGS)
Pascale Richard (1), Véronique Fressart (2), Nadia Aoutil (3), Claire Perret (4), 
Nadjim Chelghoum (5), David Alexandre Tregouet (4), Philippe Charron (3), 
Eric Villard (6) 
(1) Groupe hospitalier Pitié Salpêtrière, centre de génétique, Paris cedex 13, 
France – (2) UF cardiogénétique et myogénétique moléculaire, service de 
biochimie métabolique, Paris, France – (3) Hôpital de la Pitié Salpêtrière, centre 
de référence des maladies cardiaques héréditaires, Paris, France – (4) Université 
Pierre et Marie Curie, UMRS 937, Paris, France – (5) Université Pierre et Marie 
Curie, plateforme post génomique de la Pitié Salpêtrière (P3S), Paris, France 
– (6) Université Pierre et Marie Curie, UMRS956, Paris, France
Introduction: Inherited cardiomyopathies and arrhythmias are associated to 
mutations in an increasing number of genes. Their overall prevalence stresses the need 
for high throughput and sensitive molecular diagnosis to improve genetic counseling 
and medical management. We evaluated the strength of ngS technologies through 
simultaneous sequencing of the major causative genes described in these diseases.
Methods: We designed two successive assays: 
Assay 1: Capture of 64 genes (exons and introns: 3 Mb) using Agilent probe 
design and capture protocol followed by HiSeq2000 sequencing (Illumina). Ten DNAs 
with known causative mutations in 10 different genes were used to estimate coverage, 
sensitivity and specifi city. 
Assay 2: Based on assay 1 results, we designed a second assay on 76 genes 
(exons and intronic boundaries: 0.6 Mb) using Nimblegen-Roche technology and 
HiSeq2000 sequencing. After individual samples tagging, two target-captures on 11 
independent samples were tested: 6 DNAs were pooled then captured while 6 others 
were individually captured then multiplexed before being sequenced. 
The sequence reads were realigned to the targeted regions by multiple alignments 
(BWA) and molecular variants were identifi ed through bioinformatic pipeline (CASAVA, 
Alamut and Integrative Genomics Viewer) 
Results: Assay 1: 90% of targeted sequences were fully covered (>100X). All 
10 known mutations were re-identifi ed. Despite a correct sensitivity, we observed 
an incomplete capture of specifi c regions such as GC-rich exons and the capture of 
introns led to numerous variants with low clinical meaning. 
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Prognostic signifi cance of tricuspid regurgitation peak velocity in patients 
with heart failure and preserved ejection fraction
Nathanael Auquier, Dimitri Stepowski, Charlotte Vallet, Bertrand D’Héré, Fabrice 
Bauer, Héléne Eltchaninoff
CHU de ROUEN, cardiologie, Rouen, France
Background: In patients with heart failure and preserved ejection fraction 
(HF-PEF), tricuspid regurgitation peak velocity (TRPV) may help to stratify the clinical 
risk. Data are limited, and the purpose of this work is to investigate the prognostic 
signifi cance of TRPV in HF-PEF.
Methods and Results: Eighty fi ve consecutive patients with HF-PEF (Framingham 
criteria, EF >50% and BNP >200 pg/mL, recommendation ESC 2009) who prospectively 
underwent quantitative Doppler echocardiographic measurements were followed up for 
12 months. Of these, 48 had an overt or suspected elevated pulmonary artery pressure 
[TRVP >2.8 m/s at rest] and 28 presented cardiac events during follow-up (readmission for 
heart failure in 17 patients, and cardiac death in 11). Ising univariate analysis, patients who 
had elevated TRPV exhibited more stroke (p=0.037), and anemia (p=0.024). Furthermore, 
they had higher transmitral early E wave peak velocity (p=0.001), transmitral E/A ratio 
(p=0.029), blood to tissue E/e’ ratio (p=0.030), and larger left atrium (p=0.028). These 
patients experienced more frequently symptoms of dyspnea (p=0.006). By multivariate 
Cox regression analysis, independent predictors of cardiac events were as follows: an 
increase in mean TRPV >2.8 m/s (ROC, sensibility 77.78, specifi city 61.40, p=0.015, 
IC [1.50-18.73]), an history of ischemic heart disease (p=0.013, CI [1.53-35.12]), an 
anticoagulation therapy (p=0.033, CI [1.01-32.44]), and a smaller left ventricle end-diastolic 
diameter (p=0.003, CI [0.71-0.93]). Tricuspid regurgitation peak velocity provided 
incremental prognostic value in patients with HF-PEF (logrank, p=0.015, fi gure 1). 
Conclusions: Tricuspid regurgitation peak velocity could be useful to identify a 
high-risk subset of patients with heart failure and preserved ejection fraction. 
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Heart failure and diabetes: a fatal association: (series of 1351 patients) 
Fatima Wadrahmane, Zineb Elhonsali
CHU Ibn Rochd Casablanca, cardiologie, Casablanca, Maroc
Introduction: The prevalence of heart failure and diabetes are both increasing: 
25 to 30 % of patients with heart failure suffer from diabetes. Diabetics have more 
diastolic dysfunction because accumulation collagen in intramyocardial.
Objectives: The objectives of our study are to compare echocardiographics and 
Doppler profi les of diabetics and non diabetics.
Material and Methods: We included 1351 patients, diabetics and non diabetics, 
admitted in united of heart failure in Ibn Rochd Center of Cardiology from May 
2006 to October 2010. All patients were evaluated by echocardiography and Doppler.
Results: 1351 patients were studied, the median age was 63 years. 367 (27 %) 
are diabetics. Overall, it exists similarity of the parameters studied between the 2 
groups (D) and (ND) in terms of morphology and hemodynamics (end diastolic left 
ventricle volume; interventricular septum size; pulmonary arterial systolic pressure; left 
atrial volume…). But, we have found important differences of 3 parameters: Ejection 
fraction of left ventricle is higher (48.5 % than 35 %) in diabetics group. We found 
more segmental kinetic disorders (76 % than 50 %) and more diastolic dysfunction 
with higher fi lling pressures (51% than 34 %) in diabetic population.
Conclusions: In our study, we have found more diastolic dysfunction and more 
segmental kinetic disorders but ejection fraction of left ventricle is higher.
Assay 2: 98% of sequences were widely covered (>1000X). The two capture 
approaches led to very similar results with a perfect homogeneity between DNAs. 
This allows to reduce the cost and to increase the number of DNAs assayed per run. 
All control mutations were also re-identifi ed and new variants in not routinely tested 
genes were found in patients.
Conclusion: NGS technology seems to be a real “revolution”. The preliminary 
results with inherited cardiac diseases showed a sensitive, comprehensive, cost-effective 
and rapid method for molecular diagnosis of patients. However, this technology 
requires multiple competences in clinical diagnosis, knowledge of genes, molecular 
technology and bioinformatics pipeline. 
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Impact of sex on the prognosis of heart failure (series of 1500 patients) 
Fatima Wadrahmane, Saloua Laaraibi
CHU Ibn Rochd casablanca, cardiologie, Casablanca, Maroc
There are differences between heart failure (HF) of women and that of man in 
terms of epidemiology, pathophysiology, response to treatment and the same quality 
of care. The prognosis seems to be better among women, although the mechanism 
is not well understood. Clinical trials of HF including more men than women which 
limits our understanding of this disease in women. 
Our aim is to analyze the epidemiological profi le of women followed in united 
of heart failure in Ibn Rochd Center of Cardiology, see how they are optimized on the 
therapeutic; above demonstrate that the female sex is an independent prognostic factor. 
Our study group consists of all patients followed in united of heart failure: 1500 
patients between January 2006 and May 2011. Of the 1500 patients 975 were men 
and 525 women; the average age of men was 62±4 years vs 58±4 years in women. 
35% of men had diabetes and hypertension 47% versus 38% and 36% in women, 
28% of men had at least one coronary lesion confi rmed versus 10% in women. From 
the therapeutic 78% of men were optimized versus only 45% in women. After 1 year 
of follow up there were 8% of male deaths (3.5% of cardiovascular causes) versus 
4.2% in women (2% of cardiovascular causes). 
The results of our study are similar to those of the literature and show that women 
with heart failure are treated worse than men and that their prognosis is better than men.
